abstract |
The invention relates to diaminopyrroloquinazoline compounds of formula (I) wherein R1, Ra, Rb, Rc, Rd, Re, Rf and A are as defined in the specification and claims, which are useful for inhibiting protein tyrosine phosphatases, particularly PTP1B, and are useful for lowering blood glucose concentrations in mammals. |